{"schema_version":"secwatch.filing_event.v1","accession":"0001559053-26-000021","form_type":"8-K","ticker":"PRTA","cik":"0001559053","company_name":"PROTHENA CORP PUBLIC LTD CO","filed_at":"2026-08-06T20:16:21+00:00","discovered_at":"2026-08-06T20:18:00.324379+00:00","generated_at":"2026-08-06T20:20:05.507804+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Prothena reports Q2 net loss of $18.6M, revenue $1.0M; updates cash guidance to ~$259M","bullets":["Net loss of $18.6M in Q2 2026 vs $125.8M loss in Q2 2025; basic EPS loss $0.36 vs $2.34.","Total revenue $1.0M in Q2, $52.1M in H1 2026 (includes $50M Novo Nordisk milestone).","Cash and restricted cash $289.1M at June 30, 2026; no debt.","Updated FY 2026 year-end cash guidance to ~$259M (midpoint), down $14M from prior due to share repurchases.","Repurchased 2,243,888 shares in H1 2026 for $22.3M under $100M program; $55M milestone from BMS possible by YE."],"urls":{"canonical":"https://secwatch.observer/filing/0001559053-26-000021","json":"https://secwatch.observer/filing/0001559053-26-000021.json","markdown":"https://secwatch.observer/filing/0001559053-26-000021.md","text":"https://secwatch.observer/filing/0001559053-26-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1559053/000155905326000021/0001559053-26-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1559053/000155905326000021/prta-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:20:05.507804+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}